← All trials
NCT04931667
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2021
- Primary completion
- Jul 1, 2026
- Completion date
- Jul 1, 2026
- First posted
- Jun 18, 2021
- Last posted
- Sep 10, 2021
- Enrollment
- 300
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Biosplice TherapeuticsLead sponsor
- Biosplice TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.